Tempus AI (NASDAQ:TEM) Earns Neutral Rating from Analysts at UBS Group

UBS Group assumed coverage on shares of Tempus AI (NASDAQ:TEM) in a report published on Wednesday, Marketbeat.com reports. The firm issued a neutral rating and a $70.00 price target on the stock.

A number of other brokerages have also recently weighed in on TEM. Wolfe Research initiated coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Weiss Ratings lowered shares of Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. HC Wainwright dropped their price objective on Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Needham & Company LLC reiterated a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. Finally, Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Eleven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $69.33.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $59.01 on Wednesday. The business’s 50-day simple moving average is $55.96 and its 200-day simple moving average is $52.33. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI has a 52 week low of $40.77 and a 52 week high of $104.32. The firm has a market cap of $10.65 billion, a price-to-earnings ratio of -40.98 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.22) EPS. As a group, equities research analysts expect that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In related news, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the completion of the transaction, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at $6,361,440. This trade represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95. Following the completion of the transaction, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at approximately $27,903,789.43. This trade represents a 6.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 1,043,988 shares of company stock valued at $56,963,417. Company insiders own 24.26% of the company’s stock.

Institutional Trading of Tempus AI

Several institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. raised its position in Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after purchasing an additional 162 shares in the last quarter. Truist Financial Corp boosted its holdings in Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after purchasing an additional 194 shares in the last quarter. SeaCrest Wealth Management LLC grew its stake in shares of Tempus AI by 3.7% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after purchasing an additional 229 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in shares of Tempus AI by 64.5% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 653 shares of the company’s stock valued at $53,000 after purchasing an additional 256 shares during the period. Finally, Pathstone Holdings LLC raised its holdings in shares of Tempus AI by 1.4% in the 3rd quarter. Pathstone Holdings LLC now owns 18,338 shares of the company’s stock worth $1,480,000 after buying an additional 261 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: HC Wainwright raised its Tempus AI price target to $66 from $56 and maintained a “buy” rating, implying additional upside from recent trading levels and reinforcing bullish sentiment. Benzinga analyst coverage report
• Positive Sentiment: Tempus announced a plan to build a de-identified multimodal whole-genome dataset containing 100,000 genomes linked with longitudinal clinical data. The platform could strengthen the company’s data assets, improve AI research capabilities, and create opportunities for future pharmaceutical and healthcare partnerships. Tempus whole-genome dataset announcement
• Positive Sentiment: Tempus secured up to $9.5 million in ARPA-H funding to develop and deploy an autonomous AI agent for cardiology and heart-failure care. The award provides non-dilutive funding and validation from a U.S. government health research agency. Tempus ARPA-H award
• Positive Sentiment: ARPA-H selected six teams for a broader $62.7 million agentic cardiovascular AI program, highlighting growing public-sector investment in the market Tempus is targeting. ARPA-H cardiovascular AI program
• Neutral Sentiment: UBS, Roth Capital, and Rothschild & Co. Redburn initiated or announced coverage, but UBS reportedly assigned a neutral rating. The wider analyst attention may improve visibility while also signaling uncertainty about valuation and execution. UBS coverage of Tempus AI
• Negative Sentiment: The genomics platform and cardiovascular AI agent remain multi-year projects subject to funding milestones, clinical validation, regulatory approval, and commercialization risk. The government award is strategically positive but relatively modest compared with Tempus AI’s market value.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.